|Awarded On||August 18, 2021|
|Title||Novel tumor-specific bioactive nanoparticles for cancer therapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Arlington|
|Principal Investigator/Program Director||Kytai Nguyen|
|Cancer Sites||Breast, Lung and Bronchus|
*Pending contract negotiation
The estimated cancer incidence is about 1.8 million in the US in 2020 with over 600,000 deaths. The majority of cancer mortality comes from metastatic diseases that are treated with systemic therapies. Significant advances in systemic cancer therapies such as chemotherapy, immunotherapy and small molecule inhibitors have been made over the past several decades that have improved patient outcomes. However, these systemic therapies suffer from a lack of tumor specificity that significantly reduces their efficacy and causes multiple and severe side effects from collateral damage of normal cells, including but not limited to hair loss, nausea, fatigue, diarrhea and nerve damage. Therefore, there...